Kornimate/medical-research-clean huggingface dataset:
prospective assessment of quality of life (qol) in pediatric patients treated with radiation therapy for brain tumors and non-central nervous system (non-cns) malignancies

Conditions: Brain Tumors; Non-CNS Malignancies

Summary: in recent years, remarkable advances in medical oncology, surgery, and radiology have allowed for increasing cure rates for childhood malignancies. this success has led to an emerging understanding of the kinds of effects that treatments can have on the pediatric population and how such effects can influence pediatric cancer survivor's functioning and quality of life. it has become tremendously important to assess the long-term complications due to therapy in this growing sector of survivors and to tailor our treatments so as to minimize these late effects. the investigators at mgh are committed to improving the delivery of radiotherapy to our patients and improving the outcome for these patients. mgh has an on-site cyclotron for proton radiotherapy in order to provide the most advanced care for patients in need. proton therapy possesses a clinical advantage over standard photon therapy in that its optimal dose distribution delivers the bulk of radiation to the tumor site. this method spares the greatest volume of normal tissue, resulting in decreased short-term and long-term morbidity. through open pediatric protocols for patients treated with proton radiotherapy, the investigators aim to define and report the acute and late effects associated with treatment. the investigators also treat a number of patients off-protocol with both proton and photon radiotherapy, and are interested in reporting these patients' qol outcomes in conjunction with other clinical data that may be pertinent to the site of tumor treatment. this research is significant in that it will allow us to delineate the positive and negative effects of radiation treatment on patients' qol, highlighting points of success and exposing areas that are in need of improvement. such knowledge will be used to improve the experience of pediatric cancer survivors in the future. the aims of this study are: 1) to prospectively collect and report the qol outcomes in patients treated with radiotherapy and 2) to correlate the qol data with pertinent clinical information.

you will be asked to complete a series of questionnaires during your treatment and annually thereafter.

Eligibility criteria:
inclusion criteria: * any patient being treated with radiation therapy with curative intent * patients between the ages of 2 and 25 * patients who speak either english or spanish * patients who agree to fill out the questionnaire exclusion criteria: * patients younger than 2 years of age or over 25 * patients receiving treatment with palliative intent * patients who do not wish to participate

Keywords: pediatric patients treated with radiation therapy for brain tumors and non-cns malignancies
home-based high intensity interval training intervention for low active adults

Conditions: Cardiovascular Diseases

Summary: the purpose of this study is to examine the effect of a home-based high intensity interval training intervention on exercise among low active adults (defined as engaging in exercise 90 minutes or less per week). participants will be randomly assigned to a hiit-based intervention or a wait-list control each lasting 12 weeks (participants in the wait-list control condition will have the option of receiving the hiit intervention following the 12 weeks).

the intervention will be a 12-week high intensity interval training workout that will consist of home-based exercise sessions prescribed by the exercise counselor. the exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). the goal will be to engage in three exercise sessions per week. the participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. the exercise counselor will also engage in dialogue that will motivate the participant to exercise.

Eligibility criteria:
inclusion criteria: * 18 and older * exercising for 90 minutes or less each week * access to the internet exclusion criteria: * a history of coronary heart disease (history of myocardial infarction, symptoms of angina) * orthopedic problems that would limit physical activity participation * diabetes * stroke * osteoarthritis * any other medical condition that may make physical activity unsafe or unwise. * current or planned pregnancy * psychosis or current suicidal ideation * psychiatric hospitalization within the last six months
a phase 2, safety and dose-finding study in treatment-naive, pre-pubertal, growth hormone-deficient children

Conditions: Growth Hormone-Deficiency

Summary: the purpose of this study is to support selection of an appropriate safe and efficacious dose for study in further development.


Eligibility criteria:
criteria for inclusion: * pre-pubertal boys ≥ 3 years to ≤ 11 years and pre-pubertal girls ≥ 3 years to ≤ 10 years growth hormone (gh) insufficiency * diagnosis criteria consistent with growth hormone research society consensus guidelines * patients with a previously treated pituitary tumor must have no tumor progression for at least the past year * physician determined rate of change in height less than 2 standard deviations per age group. * written informed consent * parent or legal guardian who is capable and willing to administer the study drug. * other criteria apply, please contact the investigator for more information criteria for exclusion: * any clinically significant medical condition as determined by the investigator, that is likely to affect growth * contraindications to rhgh treatment; * history of or currently active malignancy, including pituitary tumors; * bone age, greater than chronological age or greater than 9 for girls or greater than 10 for boys within 3 months of screening. * patients with known diagnosis of diabetes or pre-diabetes * growth altering medications * allergies to the study medication components; * participation in another investigational study within 30 days of screening * any medical condition as judged by the investigator to interfere with patient participation or the objectives of the study * other criteria apply, please contact the investigator for more information

Keywords: growth hormone-deficient recombinant human growth hormone
study on proton radiotherapy of thymic malignancies

Conditions: Cardiotoxicity; Pulmonary Toxicity; Thymus Neoplasms

Summary: this is a multicentre non-randomized phase ii study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e. thymoma and thymic carcinoma) in the post-operative setting or in inoperable patients with localized disease. patients not willing or for any reason unsuitable to undergo proton treatment will be asked to participate in a follow-up assessment after the regular photon treatment in the same manner as the included patients. primary endpoints are:toxicity (e.g. cardiac and pulmonary toxicity) and local control at 5 year secondary endpoints: pfs, overall survival, quality of life, measured by eortc qlq 30 + lc 13 and relapse pattern

all doses are recorded in gy(rbe). after having checked all eligibility criteria patients will receive: * patients with radical surgery and unfavourable histology (b2, b3, c) and/or masaoka-koga stage iii, iva: 2 gy(rbe), once daily, five days a week to a total dose of 50 gy(rbe). * patients with non-radical surgery (r1 resection) regardless of stage and histology: 2.3 gy(rbe), once daily, 5 days a week to a total dose of 57.5 gy(rbe) * inoperable patients regardless of stage and histology and patients with r2 non-radical resection: 2.5 gy (rbe), once daily, 5 days a week to a total dose of 62.5 gy(rbe) * patients not willing to participate in study will receive photon therapy according to local practice (≥45 gy) induction or adjuvant chemotherapy may be used according to local practice. concomitant chemotherapy is not allowed.

Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of thymoma or thymic carcinoma. * with radical surgery: stage iii and iva and selected stage ii with type b2, b3 and thymic carcinoma according to local routine. with non-radical surgery (r1 or r2) or inoperable patient/ patient refusing surgery: stage i - iva, any histology * ps who 0 - 2. * fev1 \> 1l or \>40 % of predicted and co diffusion capacity \> 40% of predicted (postoperative measures) * age \>18 years, no upper age limit. * written informed consent from patients. exclusion criteria: * masaoka-koga stage ivb (distant metastases). * pregnancy. * serious concomitant systemic disorder incompatible with the study. * tumour motion \> 0.5 cm on two repeated 4dct

Keywords: thymoma thymic carcinoma proton radiotherapy
concurrent xeloda and radiotherapy for bone metastases

Conditions: Solid Tumors; Bone Metastases

Summary: hypothesis: radiosensitization using xeloda should improve the rate of complete pain relief. primary objective: * to determine the frequency of pain relief for the proposed regimen. secondary objective(s): * to determine the duration of pain relief and narcotic relief for the proposed regimen. * to determine the frequency of narcotic relief for the proposed regimen. * to determine the toxicity of concurrent uft and radiotherapy in patients with bone metastases.


Eligibility criteria:
inclusion criteria: 1. the patient must be 18 years of age or older. 2. the patient must have epithelial malignancy. 3. radiographic evidence of bone metastasis is required. acceptable studies include plain radiographs, radionuclide bone scans, computed tomography scans and magnetic resonance imaging. 4. the patient must have pain that appears to be related to the radiographically documented metastasis. 5. patients must have an estimated life expectancy of 3 months or greater. 6. signed study-specific informed consent. 7. karnofsky performance status  40. 8. calculated creatinine clearance \> 50 ml/min

Keywords: solid tumors bone metastases radiotherapy xeloda concurrent radiosensitization
innovative public-private partnership to target subsidized antimalarials in the retail sector

Conditions: Fever; Malaria

Summary: there are compelling medical and public health reasons to reduce unnecessary consumption of antimalarials and strong evidence to support the use of rdts in malaria case management. the primary study hypothesis to be tested is that clients who know they will receive a subsidy conditional on a positive test are more likely to opt for testing before deciding which drug to buy. the primary endpoint is whether subjects choose to be tested for malaria with a rapid diagnostic test. the secondary endpoint is whether they purchased an artemisinin combination therapy (act) or not. the primary outcome of interest is to compare the proportion of participants who choose to receive a free malaria diagnostic test when they can receive a subsidy for a discounted drug conditional on a positive test (group a compared to group b) compared to those without the offer of a conditional subsidy. the investigators will use an experimental design that randomly assigns clients to one of four groups. field workers will canvas households in the study area looking for individuals who have fever or history of fever or illness in the last 24 hours (current illness) who have not yet taken drugs or sought treatment outside the home. clients who meet the inclusion criteria and give verbal consent to participate will be randomly assigned to one of the four groups. they will be given the location and contact information for their local community health worker who can provide a malaria rapid diagnostic test if they choose to be tested. they will also complete a survey tool. one week later, the field worker will return to interview the participant and determine whether they were tested, what action they took for their illness, what medicine they purchased and how much they paid. the investigators will summarize clients' choice by the four randomized study groups.


Eligibility criteria:
inclusion criteria: * client is older than 1 year * client has fever or history of fever or feeling unwell with a malaria-like illness within the last 24 hours * client or their parent/legal guardian consents to participate exclusion criteria: * client has signs of severe disease or other problem requiring immediate referral to a community health worker (chw) / health facility * client has already sought treatment, purchased medicine or taken medicine for the current illness. note: if more than one febrile person who meet the inclusion criteria are found in a single household, all of the individuals will be enrolled in the same group, but only one individual (the first enrolled) will be used for the purposes of the analysis.

Keywords: malaria antimalarial subsidy malaria rapid diagnostic test (rdt) public-private partnership
acute cycling on executive control

Conditions: Physical Activity

Summary: this study will examine whether 10-minute bouts of cycling at various intensities will impact executive functioning (i.e., cognitive ability) as assessed by the antisaccade (as) task through a total of five visits. an antisaccade is a rapid eye movement away from a visual target. the ability to suppress making an eye movement towards a visual target gauges inhibitory control (i.e., a domain of executive functioning). in the initial visit, participants' exercise capacity will be assessed through a maximal effort cycling test. intensities for the cycling bouts (i.e., high, moderate, low) in subsequent sessions will be based upon this maximal effort cycling test. in visits 2 through 5, participants will complete an as task, followed by a 10-minute bout of cycling, and then complete the as task again. the order of cycling intensities will be randomized between participants. differences in the as task (i.e., reaction time and accuracy) will be compared between and within cycling conditions.


Eligibility criteria:
inclusion criteria: * able to read, write and understand english * full time student enrolled at western university * able to perform a ten-minute exercise task at a light intensity without health implications * have email or phone number for contacting purposes exclusion criteria: * do not have a medical condition that prevents you from exercise (e.g. heart attack in the past year, heart disease, irregular heartbeat, etc.) * do not have history of eye injury or neurological impairment * do not have an orthopaedic limitation * are not pregnant

Keywords: physical activity executive function anti-saccade
impact of early aging and menopause on the vascular responses to hypoxia

Conditions: Aging; Menopause; Hypoxia; Vasodilation

Summary: the purpose of this study is to examine hypoxic vasodilation and the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women.


Eligibility criteria:
inclusion criteria: * female assigned at birth * pre, peri- or post-menopausal * healthy weight (bmi ≥18 and ≤30 kg/m2) exclusion criteria: * male (assigned at birth) * pregnancy, breastfeeding * use of hormone replacement therapies * hysterectomy * body mass index \>30 kg/m2 * diagnosed sleep apnea * current smoking/nicotine/drug use * nerve/neurologic disease * cardiovascular, hepatic, renal, respiratory disease * blood pressure ≥140/90 mmhg * diabetes, polycystic ovarian syndrome * communication barriers * prescription medications * malignant cancer
a study to investigate the safety and effectiveness of aspheric laser refractive surgery treatments for myopia

Conditions: Myopia; Astigmatism

Summary: the objective of this study was to compare the safety and effectiveness of two versions of the bausch \& lomb zyoptix tissue saving aspheric algorithm versus the current zyoptix tissue saving algorithm when used for myopia and myopic astigmatism lasik treatment.


Eligibility criteria:
inclusion criteria: * myopia with or without astigmatism. * normal corneal topography * willing to have both eyes treated with the laser. exclusion criteria: * contraindications to lasik.
evaluation of an karajishi ts investigational blood glucose monitoring system

Conditions: Diabetes

Summary: the purpose of this study was to determine if subjects who have diabetes can operate the investigational blood glucose monitoring system (bgms) with no training and obtain valid glucose results.


Eligibility criteria:
inclusion criteria: * males and females, 18 years of age and older * people with type 1 or type 2 diabetes * able to speak, read, and understand english * willing to complete all study procedures exclusion criteria: * hemophilia or any other bleeding disorder * pregnancy * physical, visual, or neurological impairments that would make the person unable to perform testing with the bgm * previously participated in a bg monitor study using the karajishi ts bgms (or used a bayer contour ts meter) * working for a medical laboratory, hospital, or other clinical setting that involves training on and clinical use of blood glucose monitors * working for a competitive medical device company, or having an immediate family member who works for such a company * a condition which, in the opinion of the investigator or designee, would put the person or study conduct at risk
evaluation of safety and efficacy of dapagliflozin in subjects with type 2 diabetes who have inadequate glycaemic control on background combination of metformin and sulfonylurea

Conditions: Type 2 Diabetes Mellitus; High HbA1c Level; Inadequate Glycaemic Control

Summary: this study intends to compare the efficacy and safety of dapagliflozin versus placebo in patients with type 2 diabetes who have inadequate glycaemic control on a background combination of metformin and sulfonylurea.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * men or women age ≥ 18 years old * stable dose combination of metformin and sulfonylurea * hba1c ≥7.7% and ≤11.0% exclusion criteria: * type 1 diabetes mellitus or diabetes insipidus * recent cardiovascular events * kidney or urological disorders * hepatic disorders

Keywords: dapagliflozin diabetes hyperglycaemia
safety and efficacy of idp 118 in the treatment of plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the objective of the study is to evaluate the safety and efficacy of a topical lotion

the objective of the study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult subjects with moderate to severe plaque psoriasis.

Eligibility criteria:
key inclusion criteria: * male or female, of any race, at least 18 years of age (inclusive). * freely provides both verbal and written informed consent. * has an area of plaque psoriasis appropriate for topical treatment that covers a bsa of at least 3%, but no more than 12%. the face, scalp, palms, soles, axillae and intertriginous areas are to be excluded in this calculation. * is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study. * has a clinical diagnosis of psoriasis at the baseline visit with an iga score of 3 or 4. (the face, scalp, palms, soles, axillae and intertriginous areas are to be excluded in this assessment, if psoriasis is present). key exclusion criteria: * has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the investigator. * presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the investigator. * presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the investigator. * is pregnant, nursing an infant, or planning a pregnancy during the study period. * has received treatment with any investigational drug or device within 60 days or 5 drug half lives (whichever is longer) prior to the baseline visit, or is concurrently participating in another clinical study with an investigational drug or device.
evaluation coroacromial ligament thickness

Conditions: Shoulder Pain

Summary: in this study, it was aimed to determine the relationship between pathologic findings and coracoacromial ligament thickness in magnetic resonance imaging in shoulder pain patients.

the coracoacromial ligament, which is part of the coracoacromial arch, plays an important role in shoulder biomechanics, joint stability and proprioception. age-related changes due to chronic stress and cellular impairment may contribute to thickening and stiffening of the coracoacromial ligament to rupture the rotator cuff and development of shoulder pathologies such as impingement syndrome. in this study, it was aimed to determine the relationship between pathologic findings and coracoacromial ligament thickness in magnetic resonance imaging in shoulder pain patients. secondary purpose is whether the thickness of the coracoacromial ligament is indicative of shoulder pathologies.

Eligibility criteria:
inclusion criteria: * patients aged over 15 years diagnosed with shoulder pain exclusion criteria: * sensation and reflexes loss in the upper extremity * limitation in passive shoulder movements on physical examination * systemic rheumatic disease * diabetes mellitus * malignant disease * active infection * intraarticular injection * trauma * history of surgery

Keywords: shoulder pain, coracoacromial ligament thickness
pulmonary vascular dysfunction as a cause of persistent exertional dyspnea after coronavirus disease (covid-19)

Conditions: COVID-19

Summary: to identify pulmonary vascular disease in post/long-covid-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea

the aim is to identify pulmonary vascular disease in post/long-covid-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea (muscular, left cardiac, psychological, deconditioning-related causes) by investigating ventilation-perfusion (v/q) mismatch and (exercise-induced) pulmonary hypertension (ph) or right heart dysfunction.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, patients with a suspected diagnosis of post/long-covid-19 syndrome who present to our pneumology or infectious disease outpatient clinic or corresponding ward from the start of the study and whose sars-cov-2 infection was diagnosed at least 3 and not longer than 18 months prior to presentation * patients at least 3 and not longer than 18 months after a sars-cov-2 infection without post/long-covid-19 syndrome who present to our post-infection outpatient clinic for follow-up exclusion criteria: * patients who refuse to participate in the study * severe underlying chronic pulmonary, cardiac, or systemic disease (e.g., chronic obstructive pulmonary disease (copd), severe heart failure, neuromuscular disease) that was diagnosed prior to acute covid-19 disease and whose progression appears likely as the cause of dyspnea * other non pneumologic causes of dyspnea (e.g., hemoglobin \< 100 g/l) * unstable or acute disease (e.g., acute infection, acute renal failure, acute coronary syndrome) * inability to perform spiroergometry, including transient orthopedic problems, contraindications to central venous and arterial catheter placement (e.g., severe bleeding tendency).